# AV-101 Alone and in Combination With Probenecid in Healthy Subjects

> **NCT05280054** · PHASE1 · UNKNOWN · sponsor: **VistaGen Therapeutics, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Drug Drug Interaction

## Interventions

- **DRUG:** AV-101
- **DRUG:** Probenecid

## Key facts

- **NCT ID:** NCT05280054
- **Lead sponsor:** VistaGen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-23
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05280054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05280054, "AV-101 Alone and in Combination With Probenecid in Healthy Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05280054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*